Rational design of nanoparticulate drug
delivery systems (nano-DDS) for efficient
cancer therapy is still a challenge, restricted by poor drug loading, poor stability, and poor
tumor selectivity. Here, we report that simple insertion of a trisulfide bond can turn
doxorubicin homodimeric
prodrugs into self-assembled nanoparticles with three benefits: high drug loading (67.24%, w/w), high self-assembly stability, and high
tumor selectivity. Compared with
disulfide and
thioether bonds, the trisulfide bond effectively promotes the self-assembly ability of
doxorubicin homodimeric
prodrugs, thereby improving the colloidal stability and in vivo fate of
prodrug nanoassemblies. The trisulfide bond also shows higher
glutathione sensitivity compared to the conventional
disulfide bond, and this sensitivity enables efficient
tumor-specific drug release. Therefore, trisulfide bond-bridged
prodrug nanoassemblies exhibit high selective cytotoxicity on
tumor cells compared with normal cells, notably reducing the systemic toxicity of
doxorubicin. Our findings provide new insights into the design of advanced redox-sensitive nano-DDS for
cancer therapy.